Literature DB >> 9732872

Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis.

L Boring1, J Gosling, M Cleary, I F Charo.   

Abstract

Chemokines are proinflammatory cytokines that function in leukocyte chemoattraction and activation and have recently been shown to block the HIV-1 infection of target cells through interactions with chemokine receptors. In addition to their function in viral disease, chemokines have been implicated in the pathogenesis of atherosclerosis. Expression of the CC chemokine monocyte chemoattractant protein-1 (MCP-1) is upregulated in human atherosclerotic plaques, in arteries of primates on a hypercholesterolaemic diet; and in vascular endothelial and smooth muscle cells exposed to minimally modified lipids. To determine whether MCP-1 is causally related to the development of atherosclerosis, we generated mice that lack CCR2, the receptor for MCP-1 (ref. 7), and crossed them with apolipoprotein (apo) E-null mice which develop severe atherosclerosis. Here we show that the selective absence of CCR2 decreases lesion formation markedly in apoE-/- mice but has no effect on plasma lipid or lipoprotein concentrations. These data reveal a role for MCP-1 in the development of early atherosclerotic lesions and suggest that upregulation of this chemokine by minimally oxidized lipids is an important link between hyperlipidaemia and fatty streak formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9732872     DOI: 10.1038/29788

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  509 in total

Review 1.  Chemokines. Introduction.

Authors:  K Matsushima
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Gene targeting of chemokines and their receptors.

Authors:  D M Slattery; N Gerard; C Gerard
Journal:  Springer Semin Immunopathol       Date:  2000

Review 3.  Genetics of atherosclerosis: the search for genes acting at the level of the vessel wall.

Authors:  V Villa-Colinayo; W Shi; J Araujo; A J Lusis
Journal:  Curr Atheroscler Rep       Date:  2000-09       Impact factor: 5.113

4.  When it is inflamed, it hurts.

Authors:  R Baliga; J Narula
Journal:  J Nucl Cardiol       Date:  2001 Mar-Apr       Impact factor: 5.952

5.  Angiotensin II, atherosclerosis, and aortic aneurysms.

Authors:  B C Berk; J Haendeler; J Sottile
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

6.  Viral antichemokines: from pathogenesis to drug discovery.

Authors:  P M Murphy
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 7.  Chemokines in myocardial failure -- pathogenic importance and potential therapeutic targets.

Authors:  P Aukrust; J K Damås; L Gullestad; S S Frøland
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

8.  Chemokines and atherosclerosis: what Adam Smith has to say about vascular disease.

Authors:  B J Rollins
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 9.  NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?

Authors:  T Collins; M I Cybulsky
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 10.  Chemokine receptors and neural function.

Authors:  Charlene Cho; Richard J Miller
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.